Next Article in Journal
Quantitative Analysis of Differential Expression of HOX Genes in Multiple Cancers
Next Article in Special Issue
The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview
Previous Article in Journal
Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In Vivo
Previous Article in Special Issue
Small Ones to Fight a Big Problem—Intervention of Cancer Metastasis by Small Molecules

BRAF Mutated Colorectal Cancer: New Treatment Approaches

Medical Oncology Department, University Hospital Ramon y Cajal, 28034 Madrid, Spain
CIBERONC, The Ramón y Cajal Health Research Institute (IRYCIS), 28034 Madrid, Spain
Medicine School, Alcalá University, 28805 Madrid, Spain
Biomarkers and Therapeutic Targets Group and Core Facility, The Ramón y Cajal Health Research Institute (IRYCIS), CIBERONC, 28034 Madrid, Spain
Pathology department, University Hospital Ramon y Cajal, 28034 Madrid, Spain
Department of Medical Oncology, MD Anderson Cancer Center, 28033 Madrid, Spain
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cancers 2020, 12(6), 1571;
Received: 22 May 2020 / Revised: 9 June 2020 / Accepted: 10 June 2020 / Published: 14 June 2020
(This article belongs to the Special Issue Targeting Solid Tumors)
Colon cancer is one of the most frequently diagnosed malignancies in adults, considering both its incidence and prevalence. Anatomically, the right colon is considered as being from the cecum to the splenic flexure, and the left colon is from the splenic flexure to the rectum. Sidedness is a surrogate of a wide spectrum of colorectal cancer (CRC) biology features (embryology, microbiome, methylation, microsatellite instability (MSI), BRAF, aging, KRAS, consensus molecular subtypes (CMS), etc.), which result in prognostic factors. Different molecular subtypes have been identified, according to genomic and transcriptomic criteria. A subgroup harboring a BRAF mutation has been described, and represents approximately 10% of the patients diagnosed with colon cancer. This subgroup has morphological, clinical, and therapeutic characteristics that differ substantially from patients who do not carry this genetic alteration. Unfortunately, there is no established standard of care for this particular cohort of patients. This manuscript aims to study the biology of this subgroup of colon cancer, to understand the current approach in clinical research. View Full-Text
Keywords: BRAF; colorectal cancer; tyrosine kinases; immunotherapy; CXCR4 BRAF; colorectal cancer; tyrosine kinases; immunotherapy; CXCR4
Show Figures

Graphical abstract

MDPI and ACS Style

Molina-Cerrillo, J.; San Román, M.; Pozas, J.; Alonso-Gordoa, T.; Pozas, M.; Conde, E.; Rosas, M.; Grande, E.; García-Bermejo, M.L.; Carrato, A. BRAF Mutated Colorectal Cancer: New Treatment Approaches. Cancers 2020, 12, 1571.

AMA Style

Molina-Cerrillo J, San Román M, Pozas J, Alonso-Gordoa T, Pozas M, Conde E, Rosas M, Grande E, García-Bermejo ML, Carrato A. BRAF Mutated Colorectal Cancer: New Treatment Approaches. Cancers. 2020; 12(6):1571.

Chicago/Turabian Style

Molina-Cerrillo, Javier, María San Román, Javier Pozas, Teresa Alonso-Gordoa, Miguel Pozas, Elisa Conde, Marta Rosas, Enrique Grande, María L. García-Bermejo, and Alfredo Carrato. 2020. "BRAF Mutated Colorectal Cancer: New Treatment Approaches" Cancers 12, no. 6: 1571.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop